The North America Respiratory Diagnostics Market is witnessing significant growth driven by rising respiratory disorders and technological advancements. In 2025, market size was valued at USD 8,200 Million and is projected to reach USD 16,950 Million by 2035, expanding at a CAGR of 7.1% from 2024 to 2035.
The economic impact of tariffs on "North America Respiratory Diagnostics Market".
Market Growth Drivers
Increasing Incidence of Respiratory Diseases: Respiratory illnesses such as asthma, COPD, and lung infections have become more prevalent due to factors like pollution and smoking, particularly in the US and Canada. According to the American Lung Association, COPD is the third leading cause of death in the US, amplifying the need for early diagnosis. Companies like Thermo Fisher Scientific and BD (Becton, Dickinson and Company) are expanding their respiratory diagnostic product lines to meet the rising diagnostic demand and improve early detection and management.
Advancements in Molecular Diagnostic Technologies: The adoption of advanced molecular diagnostics, including PCR and next-generation sequencing, has accelerated rapid and accurate detection of various respiratory pathogens. Major players such as Abbott Laboratories have launched innovative respiratory test panels that deliver high sensitivity and specificity. These innovations support healthcare professionals in diagnosing complex respiratory infections and contribute to improved patient outcomes and faster treatment initiation.
Market Trends
Integration of Artificial Intelligence (AI) in Diagnostic Tools: AI-powered respiratory diagnostic systems are gaining momentum. For instance, Philips has been enhancing its radiology and diagnostics portfolio with AI-based imaging solutions that enable faster and more accurate detection of lung abnormalities. These tools assist clinicians in identifying subtle changes in imaging, improving diagnostic confidence and workflow efficiency across healthcare facilities in North America.
Adoption of Point-of-Care (POC) Diagnostic Devices: The trend towards decentralized healthcare is propelling the adoption of point-of-care devices for respiratory diagnostics. Cepheid, a Danaher Corporation company, offers portable molecular diagnostic systems, like the GeneXpert, allowing near-patient rapid testing for pathogens including influenza and COVID-19. This trend accelerates diagnosis and treatment, proving especially valuable for time-sensitive respiratory conditions.
Market Opportunity
Expansion in Home-based and Remote Diagnostic Solutions: The surge in telehealth and remote patient monitoring presents a substantial opportunity for companies developing at-home respiratory diagnostic kits. Companies such as ResMed are innovating connected devices capable of home-based pulmonary function testing and remote monitoring.
Rising Investment in Early Disease Detection Programs: Governments and private organizations increasingly invest in early detection and screening programs for respiratory conditions. This fosters collaborations and R&D for innovative solutions, opening doors for diagnostics manufacturers to introduce advanced, scalable products in North America.
The chart demonstrates a steady upward trajectory for the North America Respiratory Diagnostics Market revenue from 2020 to 2035. Beginning at USD 5,200 Million in 2020, the market shows consistent year-on-year growth, fueled by increased disease prevalence, innovation, and demand for rapid diagnostic solutions. By 2025, revenue reaches USD 8,200 Million, reflecting the cumulative impact of product launches and healthcare investments. The growth continues robustly through the next decade, with technological advances and an aging population further driving demand. By 2035, the market is projected to nearly double, reaching USD 16,950 Million, emphasizing the sector's strong long-term outlook.
Market by Regions Share (%), 2025
The 2025 pie chart reveals a dominant market presence in the United States, capturing 74% of the North American respiratory diagnostics market share. Canada follows with 19%, benefiting from its universal healthcare access and growing investment in diagnostic infrastructure. Mexico accounts for 5%, showing growth potential due to healthcare reforms and rising disease diagnosis rates. Other regions, including Puerto Rico and Bermuda, contribute 1% each, reflecting smaller but emerging markets. This distribution highlights a highly concentrated market, with the US leading innovation, product adoption, and revenue.
Recent Market Developments (Past 6 Months)
In April 2024, Abbott Laboratories announced the US FDA clearance of its innovative multiplex respiratory panel, enabling simultaneous detection of over 20 viral and bacterial pathogens, including COVID-19, influenza, and RSV. This development accelerates rapid respiratory illness diagnosis in hospitals and clinics, supporting healthcare providers in targeted treatment approaches amid fluctuating disease landscapes.
In February 2024, Thermo Fisher Scientific partnered with Microsoft to incorporate AI-driven data analytics into its respiratory diagnostic devices. The partnership aims to increase the accuracy and predictive capabilities of diagnostic platforms, reduce result turnaround time, and provide actionable insights for clinicians, marking a significant leap in smart diagnostics deployment across North American healthcare systems.
In March 2024, BD (Becton, Dickinson and Company) launched an expanded portfolio of point-of-care respiratory diagnostic kits in Canada, tailored for pediatric and geriatric populations. The new solutions improve rapid screening capacity for influenza and RSV, fulfilling growing demand in regional health centers and facilitating swift public health responses to seasonal respiratory outbreaks.
Press Releases